Combining Chemotherapy and Immunotherapy for the Treatment of Triple-Negative Breast Cancer

Oncology (Williston Park). 2019 Apr 15;33(4):137-40.
No abstract available

MeSH terms

  • Antibodies, Monoclonal / therapeutic use
  • Antibodies, Monoclonal, Humanized / therapeutic use
  • Antineoplastic Agents, Immunological / therapeutic use*
  • B7-H1 Antigen / antagonists & inhibitors
  • Chemotherapy, Adjuvant
  • Drug Therapy, Combination / methods*
  • Female
  • Humans
  • Lymphocytes, Tumor-Infiltrating / drug effects
  • Programmed Cell Death 1 Receptor / antagonists & inhibitors
  • Survival Analysis
  • Triple Negative Breast Neoplasms / drug therapy*
  • Triple Negative Breast Neoplasms / pathology

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Antineoplastic Agents, Immunological
  • B7-H1 Antigen
  • Programmed Cell Death 1 Receptor
  • durvalumab
  • atezolizumab
  • pembrolizumab